Study on the Synthetic Technology of a Palbociclib Side Chain Intermediate for Anti - Breast Cancer Drugs by 魏岚
学校编码：10384   分类号 密级    
学    号：X201219301027 UDC     
硕  士  学  位  论  文 
一种抗乳腺癌药物帕博西尼侧链中间体的 
合成工艺研究 
Study on the Synthetic Technology of a Palbociclib Side Chain 
Intermediate for Anti - Breast Cancer Drugs 
魏  岚 
指导教师姓名： 胡 晓 兰  副 教 授 
专  业  名  称： 材 料 工 程 
论文提交日期： 2 0 1 7 年  1 0  月 
论文答辩时间： 2 0 1 7 年  1 1  月 
学位授予日期： 2 0 1 7 年  1 2  月 
答辩委员会主席： 
评    阅 人： 



















另外，该学位论文为（                            ）课题（组）
的研究成果，获得（               ）课题（组）经费或实验室的






声明人  （签名）： 
指导教师（签名）： 
 
























（     ）1.经厦门大学保密委员会审查核定的保密学位论文，
于   年  月  日解密，解密后适用上述授权。 







                             声明人（签名）： 


























































Palbociclib was developed by Pfizer Inc. of the United States and was approved 
by the FDA on February 3, 2015. It was approved by the European Medicines Agency 
on November 9, 2016 and sold by Pfizer in the United States and Europe under the 
trade name Ibrance. Palbociclib is a small molecule inhibitor of the cyclin-dependent 
kinase (CDK4/CDK6), which was approved for use with letrozole for the treatment of 
postmenopausal estrogen receptor positive (ER +) And human epidermal growth 
factor receptor negative (HER2-) late breast cancer. 
In this paper, based on the analysis of the existing synthetic route, a 
2-aminopyridine was designed as a raw material to synthesize papoxidone side chain 
intermediate 4-(6) by bromination, oxidation, coupling and hydrogenation. 
-aminopyridin-3-yl) -piperazine-1-carboxylic acid tert-butyl ester, and the synthesis 
process was optimized. In this paper, the structures of the intermediates were 
synthesized by NMR and their purity was tested by liquid chromatography. 
First, the synthesis of 2-amino-5-bromopyridine in this paper, the use of liquid 
bromine direct bromination, the purpose is to reduce the cost of raw materials, while 
optimizing the reaction conditions, high yield, high purity 2-amino-5-bromopyridine; 
The crude product was recrystallized from methanol and the yield was 67% and the 
purity of the product was 99%. Secondly, 4-(6-nitro-2-bromo-pyridine) was oxidized 
to nitro, Pyridin-3-yl) -piperazine-1-carboxylic acid tert-butyl ester was synthesized 
by coupling with 2-nitro-5-bromopyridine and Boc-piperazine as a starting material. 
Finally, 4-(6-amino Pyridin-3-yl)-piperazine-1-carboxylic acid tert-butyl ester The 
nitro group is efficiently converted to an amino group using a clean, non-polluting 
palladium-carbon catalytic hydrogenation. 
In this paper, the synthesis process of 4-(6-aminopyridin-3-yl) 
-piperazine-1-carboxylic acid tert-butyl ester was established and the desired results 
were obtained. Industrial production provides a basis. 
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